Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.
Not an official event of the 2017 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.
This activity is supported by educational grants from Eisai Inc. and Exelixis, Inc.
The landscape of renal cell carcinoma (RCC) management has changed dramatically in recent years with the approval of new agents. The availability of these agents, along with data updates on their efficacy and safety, has complicated RCC treatment planning in terms of therapeutic selection and sequencing, toxicity management, and dose/schedule optimization. Additionally, positive results from studies of novel single-agent and combination therapies, biomarkers, and approved agents in new lines of therapy suggest more changes are on the horizon in RCC management. To help clinicians in their day-to-day practices, this case-based satellite symposium will broach a variety of clinical scenarios at key junctures in care, with the understanding that real-world scenarios cannot always be bucketed neatly into simple “lines of therapy.” The format of this activity will provide the audience with an opportunity to interact with the expert faculty panel and to reflect on how they arrive at the decisions they make, how their decisions compare with those of the faculty, whether they have a deep understanding of landmark trial results, and how to better contextualize evidence to optimize decision making at key decision points along the RCC treatment continuum.
This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of RCC. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with RCC will be invited to participate.
Upon completion of this activity, participants will be able to:
Toni K. Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Director, Kidney Cancer Center
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018